Key result
Systematic review protocol evaluates ICD outcomes and harms in catecholaminergic polymorphic ventricular tachycardia.
Why the study?
While guidelines acknowledge the anticipated benefits of ICDs in CPVT, the potential adverse effects have received less attention.
Does implantable cardioverter defibrillator (ICD) therapy reduce mortality or increase complications in patients with catecholaminergic polymorphic ventricular tachycardia compared to standard care?
Systematic Review
Does implantable cardioverter defibrillator (ICD) therapy reduce mortality or increase complications in patients with catecholaminergic polymorphic ventricular tachycardia compared to standard care?
This protocol outlines a planned systematic review and meta-analysis to evaluate the efficacy and safety of ICD therapy compared to standard medical management in patients with CPVT.
Answers are grounded in this paper and cite their sources.
Planned meta-analysis of ICDs in CPVT will address efficacy-safety gap; leaves open current clinical decisions until results emerge.
BACKGROUND: While the guidelines acknowledge the anticipated benefits of using an implantable cardioverter defibrillator (ICD) in individuals with catecholaminergic polymorphic ventricular tachycardia (CPVT). However, the potential adverse effects have received less attention. METHODS AND ANALYSIS: To address this issue comprehensively, we will explore various databases such as the Cochrane Library, Web of Science, EMBASE and PubMed. Our study will include CPVT patients, both with and without ICD implantation. Two researchers will evaluate the eligible studies independently and gather pertinent data. The quality of the studies included will be assessed using either the Newcastle-Ottawa Scale or the Cochrane Risk of Bias Tool. Data analysis will be conducted using RevMan. ETHICS AND DISSEMINATION: Because this research depends exclusively on existing studies, obtaining patient informed consent and ethics approval is unnecessary. The results of this meta-analysis will be shared at conferences or in peer-reviewed journals. PROSPERO REGISTRATION NUMBER: CRD42022370824.
No takes yet. Share an insight, caveat, or question.
Dong et al. (2024) conducted a systematic review in Catecholaminergic polymorphic ventricular tachycardia (CPVT). Implantable cardioverter defibrillator vs. Standard care or antiarrhythmic medications was evaluated on All-cause (total) mortality, fatal and non-fatal cardiovascular events, ICD harm, and ICD-related mortality. Implantable cardioverter defibrillators for patients with catecholaminergic polymorphic ventricular tachycardia are the subject of this systematic review and meta-analysis protocol, with no clinical results reported yet.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: